1. Home
  2. SAVA

SAVA

Cassava Sciences Inc.

Logo Cassava Sciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Founded: 1998 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 1.1B IPO Year: N/A
Target Price: $124.00 AVG Volume (30 days): 718.0K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.32 EPS Growth: N/A
52 Week Low/High: $12.32 - $32.10 Next Earning Date: 04-29-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: